

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Cabozantinib for treating medullary thyroid cancer [ID56]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No potential equality issues were identified during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

In the submission for vandetanib, Sanofi noted that cabozantinib and vandetanib are both currently funded via the Cancer Drugs Fund but that the two drugs are not interchangeable; therefore the potential removal of vandetanib would create inequity for patients with medullary thyroid cancer for whom cabozantinib was unsuitable, because they would not have a systemic treatment option.

Neither cabozantinib nor vandetanib were recommended for medullary thyroid cancer, therefore there are no inequities relating to access within this patient population.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues have been identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The preliminary recommendations do not make it more difficult in practice for a specific group to access the technology compared with other groups.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

There is no potential for the preliminary recommendations to have an adverse impact on people with disabilities.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Not applicable.

Approved by Associate Director (name): Helen Knight

Date: 15/08/2017

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues have been raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Cabozantinib has been recommended as a treatment option for medullary thyroid cancer. NICE is not currently in a position to release any recommendations on vandetanib because the committee's consideration of vandetanib is still ongoing. A separate document with the committee's recommendations on vandetanib will be released at a later date.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

Approved by Associate Director (name): Helen Knight

Date: 30/01/2018